Myovant Sciences (MYOV) Priced

Newly-formed biotech developing an acquired therapy for endocrine disorders.

Health Care - Biotechnology

IPO Performance
Latest Trade $11.11 0.00 (0.0%)
First Day Return -11.6%
Return from IPO -25.9%
 
Myovant Sciences IPO News more
  • .
IPO Data
IPO File Date 09/30/2016
Offer Price $15.00
Price Range $12.00 - $15.00
Offer Shares (mm) 14.5
Deal Size ($mm) 218
 
IPO Data
IPO Date 10/26/2016
Offer Price $15.00
Price Range $12.00 - $15.00
Offer Shares (mm) 14.5
Deal Size ($mm) $218
 
Underwriters
more
Business Overview
We are a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women’s health diseases and other endocrine-related disorders. Our lead product candidate is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone, or GnRH, receptor antagonist. We are advancing relugolix for the treatment of heavy menstrual bleeding associated with uterine fibroids, endometriosis-associated pain and advanced prostate cancer.
We are a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women’s health diseases and other endocrine-related disorders. Our lead product candidate is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone, or GnRH, receptor antagonist. We are advancing relugolix...
more
Company Data
Headquarters Hamilton, , Bermuda
Founded 2016
Employees 9
Website www.myovant.com
 

Performance vs. IPO Index (IPOUSA)